Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Q: What does this research mean for the field?

Etrasimod is an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P1, 4, and 5 to suppress lymphocyte emigration and improve chronic colonic inflammation in ulcerative colitis. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Satoko Nonaka-Hashida; Hirotoshi Yuasa; Ryosuke Ono; Hiroshi Hirano; Koki Fukuta; Masanori Hizue

doi:10.1254/fpj.26041

August 31, 2026Folia Pharmacologica JaponicaOpen Access

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To outline the pharmacological characteristics, receptor selectivity, and immunomodulatory mechanism of etrasimod for the management of ulcerative colitis.
Assessed the binding affinity and selectivity of etrasimod L-arginine across the five sphingosine 1-phosphate receptor subtypes (S1P1–5).
Characterized the molecular pathway of S1P1 receptor internalization and its role in sequestering lymphocytes within peripheral lymphoid organs.
Etrasimod acts as a selective, high-affinity oral modulator targeting S1P receptor subtypes 1, 4, and 5 (S1P1, S1P4, and S1P5).
Stimulation of S1P1 triggers receptor internalization on lymphocytes, suppressing their egress from local lymph nodes into inflammatory sites and alleviating chronic colonic mucosal inflammation.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Pharmacological review shows etrasimod targets S1P1,4,5 receptors to prevent lymphocyte trafficking in ulcerative colitis, suggesting a targeted oral therapy for chronic intestinal inflammation.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nonaka-Hashida et al. (2026) studied this question.

synapsesocial.com/papers/6a9934b4636c6408cfa7c775 https://doi.org/10.1254/fpj.26041

View Full Paper

Ask AI

Bookmark

Share

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading